Nanoform has announced that it is collaborating with A.forall Development and IMGA Futurum Tech Fund to create a new company, named BRAFMed, to progress the clinical development and future outlicensing of Nanoencorafenib, a patient-centric nanoformulation of encorafenib.
The signing of a Letter of Intent with respect to BRAFMed Lda was first announced by Nanoform on May 20th, 2025.
Encorafenib, sold under the brand name Braftovi, a registered trademark of Pfizer, is an orally administered anti-cancer medication.
Nanoform has developed a prototype nanoformulation with significantly higher drug load.
If successful, the nanoformed product would offer greatly improved dosing compared with that of the marketed formulation, which requires a dosing regimen of up to six 75 mg capsules taken daily.
Clinical development and manufacturing of nanoformed drug substances for evaluation will take place at Nanoform’s development and manufacturing facility in Helsinki.
"Nanoform’s performance-enhancing technologies play a significant part in the development of new and improved medicines and we are proud today to announce partnering with the clinical development and commercialisation of Nanoencorafenib, which is one of our innovative development initiatives,” said Prof. Edward Hæggström, CEO of Nanoform.
“This announcement underscores investors’ and industry players’ confidence in our technologies and we are pleased to welcome these highly experienced partners to drive this improved product forward."
“Our mission is to develop medicines that make a meaningful difference for patients," said Steen Vangsgaard, CEO of A.forall Group NV.
"By combining our skills in development, registration and commercialisation with Nanoform’s pioneering technology and unique medicines such as nanoencorafenib, we can offer treatments that improve care and outcomes."
"Together, we’re committed to giving patients hope and better health through innovation."
“IMGA is proud to support the development of Nanoencorafenib alongside Nanoform and A.forall," said Tiago Geraldes, Private Equity Director at IMGA.
"We believe that Nanoform’s advanced nanoforming technology represents a significant leap forward in patient-centric drug innovation."
"By enabling higher drug loads and more convenient dosing, this technology has the potential to transform treatment experiences and outcomes for patients."
"Our investment reflects our commitment to fostering breakthrough solutions in healthcare and bringing meaningful improvements to those who need them most."
Nanoform will continue to support the development of Nanoencorafenib with its nanoforming services and has granted an exclusive license to BRAFMed Ltd for Nanoform’s intellectual property covering Nanoencorafenib.
Under the agreement, BRAFMed Ltd will pay Nanoform service fees, low single million development milestones and up to mid-single digit tiered % royalty.
The BRAFMed Ltd partners’ target is to ultimately out-license Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or a value-added generic medicine.
With the completion of the total investment now signed, Nanoform’s fully diluted ownership in BRAFMed Ltd is expected to be 40-50%.
The investment is expected to be sufficient to finance the clinical development of Nanoencorafenib up and until its commercialisation.